inflammation and glp-1 Incretins as Multi–Disease State Treatments Molecular signals underlying the anti-inflammatory

[DOI] [PubMed] [Google Scholar] 15.Jastreboff A.M., Aronne L.J., Ahmad N.N., Wharton S., Connery L., Alves B., Kiyosue A., Zhang S., Liu B., Bunck M.C., et al

N Engl J Med 377(3):300301

States have likely pulled back on AOM coverage due to the unprecedented adoption of GLP-1s, which triggered sharp increases in pharmaceutical spending

Blood pressure medications cost $50 to $200 per month

This makes them much better suited to treatment compliance than addiction therapies which require daily administration (and it should be noted that several longer acting formulations of existing SUD medications are coming to market as well)